Company intelligence / Profile preview

Yingkai Saiwei Biotechnology

Beijing, Beijing Shi / Beijing Municipality / Beijing City / 北京市, Chinapitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

Yingkai Saiwei Biotechnology is developing a mutant KRAS G12V-specific TCR transduced T cell therapy for advanced and metastatic solid tumors. Its lead program, YK0901, is in Phase 1 clinical trials with Peking University as the sponsor. The trial targets patients with advanced malignant neoplasms harboring the KRAS G12V mutation; as of July 2023, recruitment had not yet started and no clinical results have been published.

Therapeutic areas: Oncology
Modalities: TCR-T cell therapyCell therapy
Industry: Biotech

Partnerships

Peking University

Beyond the preview

Go deeper on Yingkai Saiwei Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yingkai Saiwei Biotechnology.

Explore the full profile